Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]
Titel:
Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532]
Auteur:
Santin, Alessandro D. Filiaci, Virginia Bellone, Stefania O'Cearbhaill, Roisin Ratner, Elena S. Mathews, Cara A. Cantuaria, Guilherme Gunderson, Camille C. Rutledge, Teresa Buttin, Barbara M. Lankes, Heather A. Birrer, Michael J.